De Lorenzo Andrea, Carazza Mariana, Lima Ronaldo
Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Instituto Nacional de Cardiologia, Rio de Janeiro, Brazil.
Arch Med Sci Atheroscler Dis. 2018 Jun 28;3:e90-e95. doi: 10.5114/amsad.2018.76865. eCollection 2018.
There is still controversy about the favorable prognosis of "metabolically healthy" (MH) obese. This study evaluated mortality and the use of myocardial perfusion scintigraphy (MPS) for risk stratification of MH or metabolically unhealthy (MU) obese or nonobese patients.
Patients without dyslipidemia, hypertension, or diabetes were considered MH, and those with ≥ 1 of these risk factors were considered MU. The MPS was categorized as normal, abnormal or ischemic. Patients were followed for 4.0 ±1.0 years for all-cause death.
Of 2450 patients, 613 were obese. The MH obese patients less often had ischemia than MU obese, but there was no significant difference in the prevalence of ischemia compared to all nonobese. The annualized death rate of MH obese was 1.3% and of nonobese 1.0% ( = 0.4). An abnormal MPS and the MU status were independently associated with death, with hazard ratios of 1.85 and 1.72, respectively. A normal MPS identified patients with low risk among all subgroups; annualized rates of death were 1.0%, 1.1% and 1.0% for all nonobese, MH obese and MU obese, respectively ( = 0.63).
The annualized death rate of MH obese patients was not significantly different from that of nonobese individuals. Myocardial perfusion scintigraphy was able to stratify prognosis in the overall patient population. These data may be helpful to identify high-risk individuals, thereby improving patient management.
“代谢健康”(MH)肥胖患者的良好预后仍存在争议。本研究评估了死亡率以及心肌灌注显像(MPS)在MH或代谢不健康(MU)肥胖或非肥胖患者风险分层中的应用。
无血脂异常、高血压或糖尿病的患者被视为MH,有≥1项这些危险因素的患者被视为MU。MPS被分类为正常、异常或缺血。对患者进行4.0±1.0年的全因死亡随访。
在2450例患者中,613例为肥胖患者。MH肥胖患者发生缺血的情况比MU肥胖患者少,但与所有非肥胖患者相比,缺血患病率无显著差异。MH肥胖患者的年化死亡率为1.3%,非肥胖患者为1.0%(P=0.4)。MPS异常和MU状态与死亡独立相关,风险比分别为1.85和1.72。正常的MPS在所有亚组中识别出低风险患者;所有非肥胖、MH肥胖和MU肥胖患者的年化死亡率分别为1.0%、1.1%和1.0%(P=0.63)。
MH肥胖患者的年化死亡率与非肥胖个体无显著差异。心肌灌注显像能够对总体患者人群的预后进行分层。这些数据可能有助于识别高危个体,从而改善患者管理。